Kailera Therapeutics

We're proud to participate in the Annual Meeting of the European Association for the Study of Diabetes e.V. (EASD) and present new clinical data supporting Kailera's pipeline. #EASD2026 offers an important opportunity to highlight our commitment to obesity and connect with leaders advancing the next generation of metabolic medicines. Read our press release here: https://lnkd.in/e9xbXBCP

Kailera announced the completion of enrollment in our global Phase 3 KaiNETIC clinical program evaluating ribupatide injection, a GLP-1/GIP dual receptor agonist, and narrowed guidance for topline data to mid-2028. Learn more: https://lnkd.in/ehevMNGx

Our employees recently came together for our second annual backpack volunteer event, in partnership with Life Science Cares Boston, benefiting Children's Services of Roxbury, Inc.. Volunteers filled backpacks with school supplies to help local students start the school year with the tools they need. Having the right supplies on hand can make a meaningful difference for children and families, helping students feel prepared, confident, and ready to learn. Thank you to our #KaiCrew and everyone who volunteered! #KaileraTx

At Kailera, our shared mission brings us together and pushes us forward. It inspires us to be collaborative, creative, and make a meaningful impact. This month’s #KaiLife features Meiling May Blanchette, Associate Director, Pharmacovigilance Planning and Innovations. “I feel incredibly fortunate to work in an organization where strong leadership and a clear, consistent vision bring people together around a common goal. This shared focus not only empowers teams to innovate and collaborate, but ultimately helps us deliver better outcomes for the patients who depend on us.” #KaiLife #KaiCrew #KaileraTx

We are incredibly proud to announce that Kailera has been named a finalist for the 22nd Annual #ScripAwards in the Biotech Company of the Year category!   The Citeline Scrip Awards recognize outstanding innovation and achievement across the global biopharma industry, and we’re honored to be shortlisted alongside an impressive group of industry leaders. This recognition reflects the dedication of our team and the tremendous progress we’ve made in developing the next generation of obesity care. We are advancing a diversified pipeline of GLP-1-based therapies designed to address critical unmet needs and provide options for people living with obesity, no matter where they are in their treatment journey. A huge thank you to our team, partners, and the esteemed panel of judges. We look forward to celebrating with the biopharma community in London this December!   View the full 2026 shortlist here: https://lnkd.in/ev9Kv-5E   #ScripAwards2026 #KaileraTx #Biotech #ObesityCare

This September, Kailera will participate in two investor conferences: Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum in New York, featuring Jamie Coleman, Chief Commercial Officer, and Stifel Financial Corp.'s 2026 Virtual Cardiometabolic Forum, featuring Ron Renaud, Chief Executive Officer, Douglas Pagan, Chief Financial Officer, and Scott Wasserman, Chief Medical Officer.    We look forward to sharing recent progress advancing our pipeline of four diversified clinical-stage candidates, each designed to address critical unmet needs in the obesity treatment landscape.    Learn more: https://lnkd.in/gGMDiPCA   #KaileraTx #Obesity #ObesityCare

Progress and innovation don’t happen by accident. It takes curious minds, collaborative teams, and leaders who inspire others to think differently. This month’s #KaiLeader is Bríain Ó Hartaigh, Senior Director, Real-World Evidence & HEOR. “In my role as Senior Director of Real-World Evidence & HEOR, I lead an exceptional team focused on driving innovation through evidence generation to support our upcoming portfolio launch. We are courageous in our scientific approach, actively leaning into pioneering research and advanced methods to underline the critical unmet needs that persist in obesity management today. As we begin translating complex data into actionable insights, we look forward to contributing towards defining the true real-world potential of Kailera’s next-generation therapeutics. This journey is inherently collaborative, relying on close partnership across our internal teams to build a strong, shared foundation for our research. As Kailera continues its rapid growth, I am incredibly energized by the passionate talent we are bringing together to deliver this transformational impact for patients living with obesity.” #KaiLeaders #KaiCrew #KaileraTx 

The people and teams behind Kailera are what make our mission possible. They bring passion and purpose to our work every day, helping drive meaningful progress toward our shared goals.    This month’s #KaiLife is from Jesse Jergensen, Senior Clinical Trial Manager. “At Kailera, we are committed to delivering high-quality clinical trials while keeping participants at the center of everything we do. Our collaborative approach across teams helps us tackle challenges, continuously improve how we work, and create meaningful experiences and outcomes for participants.” #KaiLife #KaiCrew #KaileraTx 

Today, we reported financial results for the second quarter of 2026 and provided a summary of recent pipeline and corporate updates. Highlights include: - IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 - Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027 - Expanded executive team to strengthen technical operations capabilities and corporate affairs leadership - Cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028 With continued momentum across our business and pipeline, we remain focused on advancing therapies that have the potential to maximize weight loss, improve tolerability, and address other critical needs for people living with obesity and overweight. Read the full earnings announcement here: https://lnkd.in/eEMGkdkU #Obesity #ObesityCare #GLP1 #WeightManagement #KaileraTx

Today we announced Nur Nicholson as Chief Technology Officer of Kailera. Nur's expertise in building resilient, scalable manufacturing networks will be key to delivering on our mission for people living with obesity. Please join us in welcoming Nur to the team! Read the press release here: https://lnkd.in/eaNyEU-u #KaiCrew #KaileraTx